Company news

BridgeBio Pharma, Inc. news in 2024

BridgeBio Pharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

December 12, 2024

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

November 21, 2024

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 17, 2024

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

November 17, 2024

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

November 11, 2024

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

November 4, 2024

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

October 23, 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

October 2, 2024

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

September 29, 2024

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

September 26, 2024

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

September 16, 2024

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

September 9, 2024

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

September 9, 2024

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

August 29, 2024

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

August 28, 2024

BridgeBio Pharma to Participate in September Investor Events

August 27, 2024

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

August 25, 2024

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

August 18, 2024

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

July 31, 2024

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

July 22, 2024

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

June 17, 2024

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

June 5, 2024

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

June 3, 2024

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

June 2, 2024

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

May 28, 2024

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

May 23, 2024

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

May 13, 2024

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Se...

May 12, 2024

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

May 1, 2024

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

May 1, 2024

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

April 6, 2024

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

March 4, 2024

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

March 3, 2024

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

March 3, 2024

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 21, 2024

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

February 6, 2024

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

February 4, 2024

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

February 1, 2024

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

January 17, 2024

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

January 9, 2024

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

January 2, 2024

Decks in 2024